��������

Fonghsu (Jack) Kuo, Ph.D., is a scientist with extensive experience in analytical development within the biopharmaceutical industry, currently employed at Takeda since January 2019 and Shire since January 2016. Kuo's work includes analytical method development, feasibility assessments, peptide mapping analysis, and charge heterogeneity determination of monoclonal antibodies (mAb). Kuo has previously held positions as an analytical development scientist at Dyax, where responsibilities included characterizing mAb variants and supporting BLA filing, as well as conducting research as a postdoctoral researcher at Boston College. Educational qualifications include a Ph.D. in Biomedical Engineering and Biotechnology from the University of Massachusetts and a Master’s degree in Molecular Biology from Taipei Medical University.